<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39387988</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8229</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Infectious diseases and therapy</Title><ISOAbbreviation>Infect Dis Ther</ISOAbbreviation></Journal><ArticleTitle>Bridging the Gap: Delphi Consensus Statements for SARS-CoV-2 Vaccination in Immunocompromised Patients.</ArticleTitle><Pagination><StartPage>2223</StartPage><EndPage>2225</EndPage><MedlinePgn>2223-2225</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-024-01049-3</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ravkin</LastName><ForeName>Hersh D</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Internal Medicine Division, Soroka University Medical Center, Beersheba, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nesher</LastName><ForeName>Lior</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1230-0428</Identifier><AffiliationInfo><Affiliation>Infectious Disease Institute, Faculty of Health Sciences, Soroka University Medical Center, Ben-Gurion University of the Negev, 1 Rager Street, 84101, Beersheba, Israel. nesherke@bgu.ac.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Dis Ther</MedlineTA><NlmUniqueID>101634499</NlmUniqueID><ISSNLinking>2193-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">End stage</Keyword><Keyword MajorTopicYN="N">Hematologic diseases</Keyword><Keyword MajorTopicYN="N">Immunocompromised host</Keyword><Keyword MajorTopicYN="N">Renal disease</Keyword><Keyword MajorTopicYN="N">Rheumatology</Keyword><Keyword MajorTopicYN="N">Transplantation</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList><CoiStatement>Lior Nesher reports honoraria for educational lectures from Pfizer, GSK, MSD, Moderna, AstraZeneca, and Takeda and participation in advisory board for GSK, MSD, Medison and AstraZeneca. Hersh D. Ravkin reports no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>11</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39387988</ArticleId><ArticleId IdType="pmc">PMC11499500</ArticleId><ArticleId IdType="doi">10.1007/s40121-024-01049-3</ArticleId><ArticleId IdType="pii">10.1007/s40121-024-01049-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MRM, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity. 2022;55(10):1779–98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9468314</ArticleId><ArticleId IdType="pubmed">36182669</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeckh M, Pergam SA, Limaye AP, Englund J, Corey L, Hill JA. How immunocompromised hosts were left behind in the quest to control the COVID-19 pandemic. Clin Infect Dis. 2024. 10.1093/cid/ciae308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11478583</ArticleId><ArticleId IdType="pubmed">38825885</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu CC, Sandford BA. The Delphi Technique: making sense of consensus. Pract Assess Res Eval. 2007;12(1). 10.7275/pdz9-th90.</Citation></Reference><Reference><Citation>Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;2(376):e068632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8889026</ArticleId><ArticleId IdType="pubmed">35236664</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>